Missios Pavlos, Beha Janina, Bitzer Michael, Malek Nisar P
Abteilung Innere Medizin I, Medizinische Universitätsklinik, Otfried-Müller-Str. 10, 72076, Tübingen, Deutschland.
Chirurg. 2021 Nov;92(11):1011-1015. doi: 10.1007/s00104-021-01487-6.
New diagnostic tools in the field of oncology that became available with introduction of the next generation sequencing call for adjustments in the current clinical workflow. To ensure correct interpretation, newly collected data need to be processed and categorized properly. Thus, current experts in oncology need to be trained and new experts from other fields need to be recruited.
The molecular tumor board was introduced to bring experts from various specialties together. The goal is to discuss and assess complex oncological cases in the context of new molecular diagnostics and give recommendations regarding individualized therapy.
After the introduction of the molecular tumor board 2 years ago, the number of cases processed within the molecular tumor board has increased steadily. Of these patients, 70% exhibit molecular alterations that are relevant to therapy. Preliminary results indicate positive responses to the applied therapies and clear improvements in the progression-free and overall survival of patients who would have been considered "untreatable" in the classical clinical setting.
The introduction of new molecular diagnostics makes the establishment of advanced clinical structures mandatory. In this regard, the molecular tumor board continues to gain in importance. Preliminary results point towards a significant impact on the therapy of advanced malignancies. The advancements in sequencing and newly established insights into the interpretation of sequencing results will lead to new therapeutic routes. Inevitably, this will make the molecular tumor board indispensable in the future.
随着新一代测序技术的引入，肿瘤学领域出现了新的诊断工具，这就要求对当前的临床工作流程进行调整。为确保正确解读，新收集的数据需要进行妥善处理和分类。因此，当前的肿瘤学专家需要接受培训，并且需要从其他领域招募新的专家。
引入分子肿瘤学委员会，将各专业的专家聚集在一起。目标是在新的分子诊断背景下讨论和评估复杂的肿瘤病例，并就个体化治疗提出建议。
两年前引入分子肿瘤学委员会后，分子肿瘤学委员会处理的病例数量稳步增加。在这些患者中，70%表现出与治疗相关的分子改变。初步结果表明，对于在传统临床环境中被认为“无法治疗”的患者，所应用的治疗方法有积极反应，且无进展生存期和总生存期有明显改善。
新分子诊断技术的引入使得建立先进的临床结构成为必要。在这方面，分子肿瘤学委员会的重要性不断增加。初步结果表明对晚期恶性肿瘤的治疗有重大影响。测序技术的进步以及对测序结果解读的新见解将带来新的治疗途径。不可避免地，这将使分子肿瘤学委员会在未来变得不可或缺。
